Taking popular GLP-1 class weight loss drugs like Ozempic and Wegovy could be linked to a higher risk of developing osteoporosis, gout and a condition that causes severe bone softening compared to people who don’t use the medications, researchers said Monday.
An analysis using five years of medical records from tens of thousands of adults diagnosed with obesity and Type 2 diabetes showed “statistically significant increases” of the conditions, the American Academy of Orthopedic Surgeons said in a statement.
